



Revcovi™ (elapegademase-lvlr)

When requesting Revcov[™] (elapegademase-lvlr), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Revcovi is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

Coverage Guidelines

The individual must meet **all** of the following criteria for authorization:

- Has a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) confirmed by one of the following:
 - Molecular genetic testing confirming bi-allelic mutations in the *ADA* gene; OR
 - The individual has had absent or very low (less than 1% of normal) adenosine deaminase catalytic activity at baseline; AND
- Revcovi is prescribed by or in consultation with an immunologist, hematologist/ oncologist, or physician who specializes in ADA-SCID or related disorders.

Approval duration: 12 months

Dosing Recommendations

Approve up to a maximum weekly dose of 0.4 mg/kg administered by intramuscular route. (Doses may be divided into multiple injections as long as weekly cumulative maximum of 0.4 mg/kg is not exceeded.)

References

1. Revcov[®] [prescribing information]. Gaithersburg, MD: Leadiant Biosciences; December 2020.
2. Hershfield M. GeneReviews [Internet]. Updated March 16, 2017. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1483/>. Accessed on November 5, 2021.
3. Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. *Blood*. 2009;114:3524-3532.
4. Kohn DB, Hershfield MS, Puck JM, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. *J Allergy Clin Immunol*. 2019;143(3):852-863.